Salute e Benessere

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

Company Announcement Net sales of DARZALEX ®in the second quarter of 2023 totaled USD2,431 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 20 , 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ®(daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the tradename...
Nasdaq GlobeNewswire
20/07/2023

Neoss® Group signs a collaboration agreement with Osstell® AB

Dr. Robert Gottlander, CEO and President of Neoss Group, expressed, "Teaming up with Osstell, the world leader in Resonance Frequency Analysis, allows us to fuse our cutting-edge dental implant solutions with their extensive knowledge in the field of dental implant stability and osseointegration." Dr.Robert Gottlander, CEO and President of Neoss Group, expressed, "Teaming up with Osstell, the world leader in Resonance Frequency Analysis, allows us to fuse our cutting-edge dental…
PR Newswire
20/07/2023

Gout Therapeutics Market to be Worth $4.13 Billion by 2030: Grand View Research…

Read full market research report with ToC, "Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease Condition (Acute, Chronic), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report with ToC, " Gout Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, Corticosteroids, Colchicine), By Disease…
PR Newswire
20/07/2023

Clinical Trial Imaging Market to be Worth $1.97 Billion by 2030: Grand View…

Read full market research report, "Clinical Trial Imaging Market Size, Share & Trends Analysis Report By Services (Clinical Trial Design & Consultation Services, Reading & Analytical Services), By End-use, By Application, By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report, " Clinical Trial Imaging Market Size, Share & Trends Analysis Report By Services (Clinical Trial Design & Consultation…
PR Newswire
20/07/2023

HUBLOT COUNTS DOWN THE DAYS UNTIL THE FIFA WOMEN'S WORLD CUP 2023™

The women's game is going from strength to strength and Hublot – always first, different, unique – is proud to be supporting its development and taking its story of dedication, excellence and fair play to the world, inspiring a new generation of fans and players. This will be the third time the Swiss fine watchmaker has timed the FIFA Women's World Cup™, having served as Official Timekeeper at the 2015 and 2019 tournaments in Canada and France respectively. Since then, Hublot has deepened its…
PR Newswire
20/07/2023

Sathgen Therapeutics announces dosing of the first patient cohort with…

Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle. MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort. Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and...
PR Newswire
20/07/2023

Idorsia sells its Asia Pacific (ex-China) operations – including select license…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland– July20 , 2023Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex-China) region ( “Territory” ), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in those territories, to Sosei Group Corporation (TSE: 4565; 'Sosei Heptares') for a total consideration of CHF 400 million. Jean-Paul Clozel , Chief Executive Officer of Idorsia,...
Nasdaq GlobeNewswire
20/07/2023

2023 Brain Health and Disability Webinar: Leave No One Behind

Registration is now open for the free 2023 World Brain Day webinar. Join WFN on Saturday, July 22, at 12:00 p.m. GMT as experts from around the world lead a conversation on "Brain Health and Disability." Many neurological disorders can lead to loss of mobility, impaired cognitive function and increased emotional burden for people and their families, creating a degree of disability that impacts their daily life. The discussion will center on efforts to close the gaps in disability…
PR Newswire
20/07/2023

Half-year Report 2023: Essity

CEO'S COMMENTS CEO'S COMMENTS High sales growth and sharp earnings improvement "Essity performed well in the second quarter with continued high sales growth and higher margins. We are following our plan to achieve our target of a return on capital employed of above 17% by 2025. Essity has now completely exited the Russian market and the ongoing strategic review of ownership in Vinda and Consumer Tissue Private Label Europe is proceeding according to plan." Increase in sales and...
PR Newswire
20/07/2023

Hansa Biopharma half year report 2023

Clinical pipeline update Clinical pipeline update Events after reporting period Financial summary Søren Tulstrup, President and CEO of Hansa Biopharma, comments "I am pleased with the solid performance in the second quarter. The launch of Idefirix ®inEuropecontinues to track well against the key launch metrics, and we have also seen good progress in our efforts to advance a valuable pipeline of drug candidates in all our four priority therapy areas. Our progress...
PR Newswire
20/07/2023

Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue…

Press Release Crossjectsigns new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New ZealandExclusive licensing, distribution and promotion agreement for ZENEO® Midazolam in epileptic seizures in Australia and New ZealandPre-marketing payments of about €0.5m due to Crossject from AFT Dijon, France 20 July 2023 -- Crossject (ISIN: FR0011716265; Euronext:ALCJ), a specialty pharma company that...
Nasdaq GlobeNewswire
20/07/2023

Sandoz announces plans to build a Biosimilar Technical Development Center in…

Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug product development center will be an important step in expanding Sandoz' Biopharma Technical Development capabilitiesApproximately 200 full-time associates will be hired in Slovenia Basel, July 20, 2023— Sandoz, a global leader in generic and biosimilar medicines, today announced...
Nasdaq GlobeNewswire
20/07/2023

New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved…

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME)Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for people with neovascular or 'wet' age-related macular degeneration (nAMD) and DMEClinical data reiterate Vabysmo's positive anatomical outcomes, including...
Nasdaq GlobeNewswire
20/07/2023

AOU Parma chooses Deenova's RFID solution for medical device traceability and…

The D8 suite of products, including Orbit Software, Sentinel RFID Cabinet, Sentry RFID Bin, and Check-in (RFID Kanban System), identifies and tracks everything handled by the hospital pharmacy and directed to operating theatres. This enables hospitals to monitor inventory, automate and manage supply chain processes, reduce equipment loss, and improve patient safety by ensuring the availability of the right equipment in the right place at the right time. The time spent in preparing…
PR Newswire
20/07/2023

ACCESS Consensus Group: Experts Warn of an Increase in Cervical Cancer if…

"While vaccination offers population-wide protection, screening is the most impactful prevention tool at our disposal for reducing the burden of cervical cancer in the coming years. It is alarming to witness sub-optimal participation rates in many high-income countries and a widening inequity among under-screened women. Our recommendations address these challenges head-on and provide a roadmap for improved accessibility to screening services, which will support the pathway to…
PR Newswire
20/07/2023

Latest analysis of lecanemab's effect on biomarkers as well as new data on…

Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker ModificationIn addition to the key secondary endpoint of lecanemab's effect on amyloid accumulation in the brain as measured by amyloid positron emission tomography (PET), the Clarity AD study also measured multiple A/T/N+ (amyloid, tau, neurodegeneration) biomarkers involved in the pathophysiology of AD such as amyloid (Aβ1-42 in CSF, Aβ42/40 ratio in plasma), tau (p-Tau181 in cerebral spinal fluid [CSF] and plasma)…
PR Newswire
20/07/2023

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application…

According to data released by GLOBOCAN 2020, lung cancer is currently the most prevalent malignant tumor with the highest mortality rate in China. Small cell lung cancer (“SCLC”) is the most aggressive subtype of lung cancer, accounting for approximately 15%-20% of all lung cancer cases with characteristics including rapid progression, early metastasis and a poor prognosis. SCLC is divided into limited-stage small cell lung cancer (“LS-SCLC”) and ES-SCLC. For patients with LS-SCLC, standard...
Nasdaq GlobeNewswire
20/07/2023

Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and…

Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option for administering therapyTOKYO and CAMBRIDGE, Mass., July19, 2023(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters:...
Nasdaq GlobeNewswire
20/07/2023

Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key…

Key Takeaways from the Hypertension Market Report Key Takeaways from the Hypertension Market Report Discover which therapies are expected to grab the major hypertension market share @ Hypertension Market Report Hypertension Overview Hypertension, often known as high blood pressure, is a common medical condition marked by consistently high blood pressure readings. Primary hypertension and secondary hypertension are the two common types of hypertension. The most common type of...
PR Newswire
19/07/2023

Harrison.ai Welcomes Robyn Denholm As Board Director

"I'm incredibly excited to be joining the Harrison.ai Board, having been a strategic advisor to the organisation for some time now," said Denholm. "I look forward to working with the Board to realise the Harrison.ai mission to scale global healthcare capacity using AI." "I'm incredibly excited to be joining the Harrison.ai Board, having been a strategic advisor to the organisation for some time now,"said Denholm."I look forward to working with the Board to…
PR Newswire
19/07/2023

Alkermes to Report Second Quarter Financial Results on July 26, 2023

About Alkermes plcAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham…
PR Newswire
19/07/2023

Monthly information regarding the total number of voting rights and total number…

Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers ) Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 06/30/202396,250,954 Total gross of voting rights: 96,250,954 Total net* of voting rights: 96,100,982 ...
Nasdaq GlobeNewswire
19/07/2023

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating…

PARIS and CAMBRIDGE, Mass., July19, 2023(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer,today announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 immune checkpoint inhibitors for the treatment of patients with...
Nasdaq GlobeNewswire
19/07/2023

Europe Honey Market to Reach $4.24 Billion by 2028, EU-5 the Major Revenue…

Since ancient times, honey has been used in Europe for its health benefits and wound treatment. The use of honey to manufacture cough syrups, bake, and for direct consumption increased during the COVID-19 pandemic. The demand for honey from the pharmaceutical, food & beverage, personal care & cosmetics, and pet industries increased after the COVID-19 pandemic due to its nutritional value. Since ancient times, honey has been used inEuropefor its health benefits and wound treatment. The…
PR Newswire
19/07/2023
Altri  Comunicati